Some children (over the age of 18 months) may, however, require higher doses of salbutamol up to 5 mg. The diluted solution is administered as an aerosol by a suitably driven nebuliser. Pay particular attention to compounds listed as "slightly soluble" and remember that You can opt-out at any time. Intermittent positive pressure ventilation (IPPV) may be used, but is rarely necessary. The solution should not be injected or swallowed. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapsePotentially serious hypokalaemia may result from beta Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles* reported spontaneously in post-marketing data therefore frequency regarded as unknownReporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.The most common signs and symptoms of overdose with salbutamol are transient beta agonist pharmacologically mediated events, including tachycardia, tremor, hyperactivity and metabolic effects including hypokalaemia and lactic acidosis (see sections 4.4 and 4.8).Hypokalaemia may occur following overdose with salbutamol. Unopened: 3 years. Most of a dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours. This site uses cookies. Rare, very rare and unknown events were generally determined from spontaneous data. A combination of nebulised salbutamol with nebulised anticholinergics should therefore be used cautiously. It can also be used as a spike fluid to increase density. It allows continued monitoring of the benefit/risk balance of the medicinal product. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.Ventolin Respirator Solution should be used with care in patients known to have received large doses of other sympathomimetic drugs.In common with other β-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. As there may be adverse effects associated with excessive dosing the dosage or frequency of administration should only be increased on medical advice.Patients being treated with Ventolin Respirator Solution may also be receiving other dosage forms of short-acting inhaled bronchodilators to relieve symptoms.Increasing use of bronchodilators, in particular short-acting inhaled β2-agonists, to relieve symptoms, indicates deterioration of asthma control. The finished reaction is: 2 KCl(aq) + Pb(NO 3) 2 (aq) → 2 KNO 3 (aq) + PbCl 2 (s) The solubility rules are a useful guideline to predict whether a compound will dissolve or form a precipitate. There were no adverse effects on fertility in animals (see section 5.3).Adverse events are listed below by system organ class and frequency. As with the majority of drugs, there is little published evidence of the safety of salbutamol in the early stages of human pregnancy, but in animal studies there was evidence of some harmful effects on the foetus at very high dose levels.As salbutamol is probably secreted in breast milk, its use in nursing mothers requires careful consideration. Intermittent administration. Concurrent administration of corticosteroids can exaggerate this effect. This information is intended for use by health professionalsAqueous, colourless to light yellow solution, pH 3.5, providing 5 mg/ml of salbutamol (as Salbutamol Sulfate BP).Ventolin Respirator Solution is indicated in adults, adolescents and children aged 4 to 11 years.